Recursion Pharmaceuticals Ownership | Who Owns Recursion Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Recursion Pharmaceuticals Ownership Summary


Recursion Pharmaceuticals is owned by 77.62% institutional investors, 3.94% insiders, and 18.44% retail investors. Vanguard group is the largest institutional shareholder, holding 9.53% of RXRX shares. ARK Innovation ETF is the top mutual fund, with 4.19% of its assets in Recursion Pharmaceuticals shares.

RXRX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockRecursion Pharmaceuticals77.62%3.94%18.44%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group39.78M9.53%$194.13M
Ark investment management33.55M8.04%$163.70B
Blackrock funding, inc. /de31.74M7.60%$154.89M
Blackrock17.31M7.33%$129.83M
Baillie gifford23.98M5.75%$117.02B
State street18.27M4.38%$89.15M
Softbank group14.67M3.51%$71.58M
Kinnevik ab (publ)13.43M3.22%$65.56M
Mubadala investment co pjsc12.99M3.11%$63.37M
Mic capital management uk llp9.64M2.31%$47.06M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Dcvc opportunity fund ii gp3.95M100.00%$19.28M
Kinnevik ab (publ)13.43M100.00%$65.56M
Data collective iv gp5.94M42.65%$28.99M
Mic capital management uk llp9.64M9.41%$47.06M
Nan fung group595.29K4.87%$2.91M
Novo7.93M2.49%$38.70M
Pivotal bioventure partners investment advisor595.52K1.68%$2.91M
Green alpha advisors212.20K1.00%$1.04M
Nvidia7.71M0.98%$37.61M
Ark investment management33.55M0.97%$163.70B

Top Buyers

HolderShares% AssetsChange
State street18.27M0.00%7.09M
Blackrock17.31M0.00%4.99M
Vanguard group39.78M0.00%3.71M
Norges bank3.47M0.00%3.47M
Blackrock funding, inc. /de31.74M0.00%3.37M

Top Sellers

HolderShares% AssetsChange
Ra capital management---7.73M
Fmr3.23M0.00%-2.36M
Deerfield management company, l.p. (series c)---2.31M
Novo7.93M2.49%-1.74M
Laurion capital management lp---1.55M

New Positions

HolderShares% AssetsChangeValue
Norges bank3.47M0.00%3.47M$23.43M
Pictet & cie (europe) sa1.63M0.16%1.63M$7.95M
Jane street group721.55K0.00%721.55K$3.52B
American century companies316.18K0.00%316.18K$1.54M
Trexquant investment lp228.75K0.01%228.75K$1.12M

Sold Out

HolderChange
Tfc financial management-1.00
Nbc securities-1.00
Twin peaks wealth advisors-4.00
Financial gravity asset management-4.00
Householder group estate & retirement specialist-11.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2025331-6.76%323,965,3964.44%771.41%170-3.41%78-8.24%
Jun 30, 2025341-2.01%308,955,6177.04%741.44%170-16.67%8521.43%
Mar 31, 20253504.79%304,203,724-0.17%750.65%2042.51%7214.29%
Dec 31, 202430810.79%289,638,35211.01%1021.20%18116.77%5612.00%
Sep 30, 2024275-1.43%260,863,9783.59%920.81%154-13.97%49-

Top Mutual Funds Shareholders


HolderShares% HoldingChange
ARK Innovation ETF18.29M4.19%-280.38K
ARK Disruptive Innovation Full Composite18.19M4.19%-1.10M
Scottish Mortgage Ord18.17M4.19%-
Vanguard Total Stock Mkt Idx Inv12.16M2.80%-259.15K
ARK Genomic Revolution11.44M2.63%-1.17M
ARK Genomic Revolution ETF11.42M2.62%-40.75K
Vanguard Small Cap Index9.22M2.12%-56.27K
Vanguard US Total Market Shares ETF8.01M1.99%1.01M
iShares Russell 2000 ETF8.18M1.87%-
Vanguard Small Cap Growth Index Inv5.21M1.20%-1.90K

Recent Insider Transactions


DateNameRoleActivityValue
Dec 04, 2025Gibson Christopher Chief Executive OfficerSell$185.20K
Dec 02, 2025Borgeson Blake-Sell$961.40K
Nov 19, 2025Gibson Christopher Chief Executive OfficerSell$166.40K
Nov 04, 2025Gibson Christopher Chief Executive OfficerSell$208.40K
Oct 23, 2025Gibson Christopher Chief Executive OfficerSell$570.00K

Insider Transactions Trends


DateBuySell
2025 Q4-6
2025 Q3-6
2025 Q2--
2025 Q1-7
2024 Q4-15

RXRX Ownership FAQ


Who Owns Recursion Pharmaceuticals?

Recursion Pharmaceuticals shareholders are primarily institutional investors at 77.62%, followed by 3.94% insiders and 18.44% retail investors. The average institutional ownership in Recursion Pharmaceuticals's industry, Biotech Stocks , is 45.22%, which Recursion Pharmaceuticals exceeds.

Who owns the most shares of Recursion Pharmaceuticals?

Recursion Pharmaceuticals’s largest shareholders are Vanguard group (39.78M shares, 9.53%), Ark investment management (33.55M shares, 8.04%), and Blackrock funding, inc. /de (31.74M shares, 7.60%). Together, they hold 25.17% of Recursion Pharmaceuticals’s total shares outstanding.

Does Blackrock own Recursion Pharmaceuticals?

Yes, BlackRock owns 7.33% of Recursion Pharmaceuticals, totaling 17.31M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 129.83M$. In the last quarter, BlackRock increased its holdings by 4.99M shares, a 40.49% change.

Who is Recursion Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Dcvc opportunity fund ii gp is Recursion Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 100.00% of its assets in 3.95M Recursion Pharmaceuticals shares, valued at 19.28M$.

Who is the top mutual fund holder of Recursion Pharmaceuticals shares?

ARK Innovation ETF is the top mutual fund holder of Recursion Pharmaceuticals shares, with 4.19% of its total shares outstanding invested in 18.29M Recursion Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools